Study of GEMOX(Gemcitabine/Oxaliplatin) Versus XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma
Biliary Tract (Intrahepatic, Extrahepatic Cholangiocarcinoma, Gall Bladder) Cancer
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Gallbladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Source: Gallbladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Previously unsuspected gallbladder cancer that is incidentally discovered in the mucosa of the gallbladder during pathological examination is curable in more than 80% of patients. However, symptomatic gallbladder cancer that is suspected prior to surgery often penetrates the muscularis and serosa. This type of gallbladder cancer is curable in less than 5% of patients.
One study reported the patterns of lymph node spread from gallbladder cancer and outcomes of patients with metastases to lymph nodes in 111 consecutive surgical patients in a single institution from 1981 to 1995.[1][Level of evidence C1] The standard surgical procedure was removal of the gallbladder, a wedge resection of the liver, resection of the extrahepatic bile duct, and resection of the regional (N1 and N2) lymph nodes. Kaplan-Meier estimates of the 5-year survival rates were 42.5% ± 6.5% for patients with node-negative tumors pathologically staged as T2 to T4 and 31% ± 6.2% for patients with similar node-positive tumors.
Sources: 1 · Level of evidence C1
Treatment options for localized and locally advanced gallbladder cancer include:
Surgery.
Sources: Surgery
External-beam radiation therapy (EBRT).
Clinical trials exploring the use of radiation therapy and radiosensitizer drugs to improve local control.
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Gallbladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
In patients with previously unsuspected gallbladder cancer that is discovered in the surgical specimen after a routine gallbladder operation and confined to mucosa (T1), most disease is cured.[2,3] During laparoscopic removal of an unsuspected cancer, implantation of carcinoma at all port sites (including the camera site) is possible.[4] All port sites are typically excised completely, even for stage I cancers.
The need for reexploration for more extended resection in incidentally discovered T1b disease is controversial. A multicenter retrospective review identified lymph node metastases in 12% of patients who underwent re-resection after cholecystectomy, but there are no prospective data regarding relative outcome with a second surgery in these patients.[5][Level of evidence C2]
Sources: 5 · Level of evidence C2
Patients with T2 or T3 disease have higher rates of unsuspected invasive disease at the time of diagnosis. A multicenter retrospective review was performed in patients who underwent re-resection after carcinoma was discovered incidentally. Residual disease was present in 57% of patients with T2 disease (including 31% with lymph node involvement and 10% with liver involvement) and in 77% of patients with T3 disease (including 46% with lymph node metastases and 36% with liver involvement).[5] On the basis of these observations, eligible patients may undergo reexploration to resect liver tissue near the gallbladder bed, portal lymph nodes, and lymphatic tissue in the hepatoduodenal ligament. Retrospective analyses suggest that extended re-resection can delay recurrences and potentially improve survival.[6-8][Level of evidence C2]
Sources: 5 · 6 · 8 · Level of evidence C2
For patients with locoregional lymph node involvement (at the cystic duct, common bile duct, hepatic artery, and portal vein), long-term disease-free survival can occasionally be achieved with radical resection. In patients with jaundice (stage III or stage IV), preoperative percutaneous transhepatic biliary drainage for relief of biliary obstruction should be considered.
Surgery with curative intent is not considered possible in patients with metastatic spread beyond the locoregional lymph nodes or to distant organs.
Source: Gallbladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
The use of EBRT with or without chemotherapy as a primary treatment has been reported to produce short-term disease control in small groups of patients. Similar benefits have been reported for radiation therapy, with or without chemotherapy, administered after resection.[9,10]
There are no phase III studies to support the use of adjuvant radiation therapy, even for patients with high-risk localized disease.
Source: Gallbladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Source: Gallbladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Unresectable, metastatic, and recurrent gallbladder cancers are not curable. Symptoms can be significantly improved with relief of biliary obstruction. A few patients have very slow-growing tumors and may live several years. Patients with unresectable, metastatic, or recurrent gallbladder cancer should consider enrolling in clinical trials whenever possible. Information about ongoing clinical trials is available from the NCI website.
Sources: NCI website
Treatment options for unresectable, metastatic, or recurrent gallbladder cancer include:
Percutaneous transhepatic drainage or endoscopically placed stents, or surgical bypass.
Sources: Percutaneous transhepatic drainage or endoscopically placed stents, or surgical bypass
Systemic therapy.
Sources: Systemic therapy
Source: Gallbladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Relief of biliary obstruction is warranted when symptoms such as pruritus and hepatic dysfunction outweigh other symptoms of the cancer. The preferred approach is percutaneous transhepatic drainage or endoscopically placed stents.[1] Surgical bypass may be appropriate when these approaches are infeasible.
Sources: 1
Palliative radiation therapy after biliary drainage may be beneficial. Patients may be candidates for inclusion in clinical trials that explore ways to improve the effects of radiation therapy with various radiosensitizers, such as hyperthermia, radiosensitizer drugs, or cytotoxic chemotherapeutic agents.
Source: Gallbladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Systemic therapy is appropriate for selected patients with adequate performance status and intact organ function. Fluoropyrimidines, gemcitabine, platinum agents, and docetaxel have produced transient partial remissions in a few patients. The incidence of gallbladder cancer is low, and clinical trials often enroll patients with all subsites of biliary tract cancers. Therefore, data must be interpreted with caution when applied specifically to patients with gallbladder cancer. In clinical practice, treatment algorithms in advanced disease often follow those with biliary tract cancer, relying on extrapolation from other trials. In this section, only current landmark studies, or those that specifically enrolled patients with gallbladder cancer, have been explicitly summarized. For more information, see Bile Duct Cancer (Cholangiocarcinoma) Treatment.
Source: Gallbladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
The DPYD gene encodes an enzyme that catabolizes pyrimidines and fluoropyrimidines, like capecitabine and fluorouracil. An estimated 1% to 2% of the population has germline pathogenic variants in DPYD, which lead to reduced DPD protein function and an accumulation of pyrimidines and fluoropyrimidines in the body.[2,3] Patients with the DPYD*2A variant who receive fluoropyrimidines may experience severe, life-threatening toxicities that are sometimes fatal. Many other DPYD variants have been identified, with a range of clinical effects.[2-4] Fluoropyrimidine avoidance or a dose reduction of 50% may be recommended based on the patient's DPYD genotype and number of functioning DPYD alleles.[5-7] DPYD genetic testing costs less than $200, but insurance coverage varies due to a lack of national guidelines.[8] In addition, testing may delay therapy by 2 weeks, which would not be advisable in urgent situations. This controversial issue requires further evaluation.[9]
Evidence (systemic therapy):
In a phase III study, 410 patients with unresectable metastatic, or recurrent biliary tract cancer were randomly assigned to receive up to 6 months of gemcitabine with or without cisplatin.[10]
Sources: 10
In a phase III study, 410 patients with unresectable metastatic, or recurrent biliary tract cancer were randomly assigned to receive up to 6 months of gemcitabine with or without cisplatin.[10]
With a median follow-up of 8.2 months, the median overall survival (OS) was superior for patients who received combination chemotherapy (11.7 months vs. 8.1 months; hazard ratio [HR], 0.64; 95% confidence interval [CI], 0.52–0.80; P < .001).[10][Level of evidence A1]
Sources: 10 · Level of evidence A1
A similar median OS benefit was demonstrated in all subgroups, including 149 patients with gallbladder cancer.
Grade 3 and 4 toxicities occurred with similar frequency in both study arms, except for increased hematologic toxic effects in patients who received gemcitabine plus cisplatin and increased hepatotoxicity in patients who received single-agent gemcitabine.
An international, multicenter, phase III study (TOPAZ-1 [NCT03875235]) included 685 patients with previously untreated and unresectable locally advanced, recurrent, or metastatic biliary tract cancer. Patients were randomly assigned to receive either durvalumab or placebo with cisplatin plus gemcitabine for up to eight cycles, followed by durvalumab or placebo maintenance until disease progression or unacceptable toxicity. After a median follow-up of 23.4 months for patients in the durvalumab group, the following was observed:[11,12]
An international, multicenter, phase III study (TOPAZ-1 [NCT03875235]) included 685 patients with previously untreated and unresectable locally advanced, recurrent, or metastatic biliary tract cancer. Patients were randomly assigned to receive either durvalumab or placebo with cisplatin plus gemcitabine for up to eight cycles, followed by durvalumab or placebo maintenance until disease progression or unacceptable toxicity. After a median follow-up of 23.4 months for patients in the durvalumab group, the following was observed:[11,12]
The primary end point of median OS was 12.9 months in the durvalumab group and 11.3 months in the placebo group (HR, 0.76; 95% CI, 0.64–0.91). In the durvalumab group, the 18-month OS rate was 35.1%, and the 24-month OS was 24.9%. In the placebo group, the 18-month OS rate was 25.5%, and the 24-month OS rate was 10.4%.[11,12][Level of evidence A1]
Sources: 11 · 12 · Level of evidence A1
There was no significant difference between groups in the number of grade 3 or 4 treatment-related adverse events or the number of events leading to discontinuation of a study medication.
An international, multicenter, phase III study (KEYNOTE-966 [NCT04003636]) enrolled 1,069 patients with previously untreated unresectable, locally advanced or metastatic biliary tract cancer. Patients were randomly assigned to receive either pembrolizumab or placebo for up to 35 cycles. This was combined with gemcitabine (with no maximum duration) and cisplatin for up to 8 cycles. After a median follow-up of 25.6 months, the following results were observed:[13][Level of evidence A1]
Sources: KEYNOTE-966 · 13 · Level of evidence A1
An international, multicenter, phase III study (KEYNOTE-966 [NCT04003636]) enrolled 1,069 patients with previously untreated unresectable, locally advanced or metastatic biliary tract cancer. Patients were randomly assigned to receive either pembrolizumab or placebo for up to 35 cycles. This was combined with gemcitabine (with no maximum duration) and cisplatin for up to 8 cycles. After a median follow-up of 25.6 months, the following results were observed:[13][Level of evidence A1]
The median OS was 12.7 months in the pembrolizumab group and 10.9 months in the placebo group (HR, 0.83; 95% CI, 0.72–0.95; one-sided P = .0034).
There was no difference in the total frequency of treatment-related adverse events between treatment groups, including grade 3 or grade 4 events. Death due to treatment-related adverse events was seen in a total of eight patients (2%) in the pembrolizumab arm and three patients (1%) in the placebo arm.
A three-arm randomized phase III study of patients with unresectable gallbladder cancer compared best supportive care (n = 27), fluorouracil plus folinic acid (FUFA) weekly for 30 weeks (n = 28), and modified gemcitabine plus oxaliplatin (mGEMOX) for up to six 21-day cycles.[14][Level of evidence A1]
Sources: 14 · Level of evidence A1
A three-arm randomized phase III study of patients with unresectable gallbladder cancer compared best supportive care (n = 27), fluorouracil plus folinic acid (FUFA) weekly for 30 weeks (n = 28), and modified gemcitabine plus oxaliplatin (mGEMOX) for up to six 21-day cycles.[14][Level of evidence A1]
With a median follow-up of 9 months, the OS was 4.5 months for patients who received best supportive care (95% CI, 0.2−8.8), 4.6 months for patients who received FUFA (95% CI, 3−6.2), and 9.5 months for patients who received mGEMOX (95% CI, 5−14; P = .039).
The only significant difference in grade 3 or 4 toxicities between the chemotherapy arms was transaminitis, which was more prevalent in the mGEMOX arm (P = .04).
A phase III noninferiority study (NCT01470443) enrolled 114 patients with metastatic biliary tract cancers, including 30 (26%) with primary gallbladder cancer. Patients were randomly assigned to receive either capecitabine plus oxaliplatin (XELOX) or gemcitabine plus oxaliplatin (GEMOX).[15][Level of evidence B1]
Sources: NCT01470443 · 15 · Level of evidence B1
A phase III noninferiority study (NCT01470443) enrolled 114 patients with metastatic biliary tract cancers, including 30 (26%) with primary gallbladder cancer. Patients were randomly assigned to receive either capecitabine plus oxaliplatin (XELOX) or gemcitabine plus oxaliplatin (GEMOX).[15][Level of evidence B1]
OS was not significantly different, at 10.4 months (95% CI, 8.0−12.6) for patients in the GEMOX group and 10.6 months (95% CI, 7.3−15.5) for patients in the XELOX group (P = .131).
The primary end point of 6-month progression-free survival (PFS) rates were 44.6% for the GEMOX group and 46.7% for the XELOX group (95% CI of difference in 6-month PFS rate, -12% to 16%, meeting criteria for noninferiority).
A predefined subgroup analysis based on the primary site of disease was performed. The analysis did not reveal a difference in objective response rate between the two arms in patients with gallbladder cancer (P = .598).
Pending additional clinical trials, cisplatin plus gemcitabine is considered the reference standard chemotherapy backbone for patients with unresectable, metastatic, or recurrent gallbladder cancer. Extrapolating from the results of the TOPAZ-1 and KEYNOTE-966 trials for biliary tract cancer, addition of a checkpoint inhibitor (durvalumab or pembrolizumab) to first-line therapy has become the standard of care. Potential alternative regimens include gemcitabine plus capecitabine, GEMOX, and XELOX. All patients should consider clinical trials.
All patients with unresectable, metastatic, or recurrent disease who have not already received checkpoint inhibitors should undergo molecular testing for deficient mismatch repair (dMMR) or microsatellite instability (MSI-H). Extrapolating from a subgroup of patients with gastrointestinal and hepatopancreatobiliary tumors in the I-PREDICT (NCT02534675) and KEYNOTE-158 (NCT02628067) studies, patients with either dMMR or MSI-H tumors can be considered for treatment with pembrolizumab.[16,17][Level of evidence C3]
Sources: I-PREDICT · KEYNOTE-158 · 16 · 17 · Level of evidence C3
Additional testing for IDH1 variants, FGFR2 gene fusions, and HER2 expression may provide potential targets in clinical trials. In clinical practice, targeted treatments that have been approved by the U.S. Food and Drug Administration as second-line treatments for patients with cholangiocarcinoma could likely be used to treat appropriate patients with gallbladder cancer. Compelling treatment options for these patients are scarce. For more information, see the Targeted therapy section in Bile Duct Cancer (Cholangiocarcinoma) Treatment.
Sources: Targeted therapy
Source: Gallbladder Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 10, 2025. Captured 2026-09-09.
The prognosis and treatment options depend on:
Sources: prognosis
the stage of the cancer (whether the cancer has spread from the gallbladder to other places in the body)
whether the cancer can be completely removed by surgery
the type of gallbladder cancer (how the cancer cell looks under a microscope)
whether the cancer has just been diagnosed or has recurred (come back)
Treatment may also depend on the age and general health of the patient and whether the cancer is causing signs or symptoms.
Gallbladder cancer can be cured only if it is found before it has spread, when it can be removed by surgery. If the cancer has spread, palliative treatment can improve the patient's quality of life by controlling the symptoms and complications of this disease.
Sources: cured · palliative treatment · quality of life · complications
Source: Gallbladder Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 10, 2025. Captured 2026-09-09.
Source: Gallbladder Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 10, 2025. Captured 2026-09-09.
Cancer is found in the wall of the gallbladder and can be completely removed by surgery.
Source: Gallbladder Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 10, 2025. Captured 2026-09-09.
Unresectable cancer cannot be removed completely by surgery. Most patients with gallbladder cancer have unresectable cancer.
Sources: Unresectable
Recurrent cancer is cancer that has recurred (come back) after it has been treated. Gallbladder cancer may come back in the gallbladder or in other parts of the body.
Sources: Recurrent
Metastasis is the spread of cancer from the primary site (place where it started) to other places in the body. Metastatic gallbladder cancer may spread to surrounding tissues, organs, throughout the abdominal cavity, or to distant parts of the body.
Sources: Metastasis · abdominal · cavity
Source: Gallbladder Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 10, 2025. Captured 2026-09-09.
Source: Gallbladder Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 10, 2025. Captured 2026-09-09.
There are different types of treatment for patients with gallbladder cancer.
The following types of treatment are used:
The following types of treatment are used:
Surgery
Radiation therapy
Chemotherapy
New types of treatment are being tested in clinical trials.
New types of treatment are being tested in clinical trials.
Radiation sensitizers
Targeted therapy
Immunotherapy
Treatment for gallbladder cancer may cause side effects.
Patients may want to think about taking part in a clinical trial.
Patients can enter clinical trials before, during, or after starting their cancer treatment.
Follow-up care may be needed.
Source: Gallbladder Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 10, 2025. Captured 2026-09-09.
Different types of treatments are available for patients with gallbladder cancer. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.
Sources: standard · clinical trials · research study
Source: Gallbladder Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 10, 2025. Captured 2026-09-09.
Source: Gallbladder Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 10, 2025. Captured 2026-09-09.
Gallbladder cancer may be treated with a cholecystectomy, surgery to remove the gallbladder and some of the tissues around it. Nearby lymph nodes may be removed. A laparoscope is sometimes used to guide gallbladder surgery. The laparoscope is attached to a video camera and inserted through an incision (port) in the abdomen. Surgical instruments are inserted through other ports to perform the surgery. Because there is a risk that gallbladder cancer cells may spread to these ports, tissue surrounding the port sites may also be removed.
Sources: lymph nodes · laparoscope · video camera · incision · abdomen
If the cancer has spread and cannot be removed, the following types of palliative surgery may relieve symptoms:
Sources: palliative · symptoms
Biliary bypass: If the tumor is blocking the bile duct and bile is building up in the gallbladder, a biliary bypass may be done. During this operation, the doctor will cut the gallbladder or bile duct in the area before the blockage and sew it to the small intestine to create a new pathway around the blocked area.
Sources: Biliary bypass · bile duct · bile · small intestine
Endoscopic stent placement: If the tumor is blocking the bile duct, surgery may be done to put in a stent (a thin tube) to drain bile that has built up in the area. The doctor may place the stent through a catheter that drains the bile into a bag on the outside of the body or the stent may go around the blocked area and drain the bile into the small intestine.
Sources: Endoscopic · stent · catheter
Percutaneous transhepatic biliary drainage: A procedure done to drain bile when there is a blockage and endoscopic stent placement is not possible. An x-ray of the liver and bile ducts is done to locate the blockage. Images made by ultrasound are used to guide placement of a stent, which is left in the liver to drain bile into the small intestine or a collection bag outside the body. This procedure may be done to relieve jaundice before surgery.
Sources: Percutaneous transhepatic biliary drainage · x-ray · liver · ultrasound · jaundice
Source: Gallbladder Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 10, 2025. Captured 2026-09-09.
Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. External radiation therapy uses a machine outside the body to send radiation toward area of the body with cancer.
Sources: Radiation therapy · radiation · External radiation therapy
Source: Gallbladder Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 10, 2025. Captured 2026-09-09.
Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping the cells from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic therapy).
Sources: Chemotherapy · injected
Source: Gallbladder Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 10, 2025. Captured 2026-09-09.
This summary section describes treatments that are being studied in clinical trials. It may not mention every new treatment being studied. Information about clinical trials is available from the NCI website.
Sources: NCI website
Source: Gallbladder Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 10, 2025. Captured 2026-09-09.
Clinical trials are studying ways to improve the effect of radiation therapy on tumor cells, including:
Hyperthermia therapy: A treatment in which body tissue is exposed to high temperatures to damage and kill cancer cells or to make cancer cells more sensitive to the effects of radiation therapy and certain anticancer drugs.
Sources: Hyperthermia therapy · anticancer
Radiosensitizers: Drugs that make tumor cells more sensitive to radiation therapy. Giving radiation therapy together with radiosensitizers may kill more tumor cells.
Sources: Radiosensitizers
Source: Gallbladder Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 10, 2025. Captured 2026-09-09.
Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells. The following targeted therapies are being studied in patients with gallbladder cancer that is locally advanced and cannot be removed by surgery or has spread to other parts of the body:
Sources: Targeted therapy · locally advanced
Ivosidenib is a type of targeted therapy that blocks a specific mutation in a gene called IDH1. It works by slowing or stopping the growth of cancer cells.
Sources: Ivosidenib · mutation · IDH1
Pemigatinib is a type of targeted therapy that blocks specific changes in a gene called FGFR2. This may help keep cancer cells from growing and may kill them.
Sources: Pemigatinib · gene · FGFR2
Source: Gallbladder Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 10, 2025. Captured 2026-09-09.
Immunotherapy is a treatment that uses the patient's immune system to fight cancer. Substances made by the body or made in a laboratory are used to boost, direct, or restore the body's natural defenses against cancer.
Sources: Immunotherapy · immune system
Immune checkpoint inhibitor therapy is a type of immunotherapy that may be used to treat gallbladder cancer.
Sources: Immune checkpoint inhibitor · therapy
PD-1 and PD-L1 inhibitor therapy: PD-1 is a protein on the surface of T cells that helps keep the body's immune responses in check. PD-L1 is a protein found on some types of cancer cells. When PD-1 attaches to PD-L1, it stops the T cell from killing the cancer cell. PD-1 and PD-L1 inhibitors keep PD-1 and PD-L1 proteins from attaching to each other. This allows the T cells to kill cancer cells.
PD-1 and PD-L1 inhibitor therapy: PD-1 is a protein on the surface of T cells that helps keep the body's immune responses in check. PD-L1 is a protein found on some types of cancer cells. When PD-1 attaches to PD-L1, it stops the T cell from killing the cancer cell. PD-1 and PD-L1 inhibitors keep PD-1 and PD-L1 proteins from attaching to each other. This allows the T cells to kill cancer cells.
Pembrolizumab is a type of PD-1 inhibitor that may be used in patients whose cancer is locally advanced and cannot be removed by surgery or has spread to other parts of the body.
Sources: Pembrolizumab
Durvalumab is a type of PD-L1 inhibitor that is being studied in combination with chemotherapy in previously untreated patients whose cancer is locally advanced, recurrent, or has spread to other parts of the body.
Sources: Durvalumab · recurrent
Source: Gallbladder Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 10, 2025. Captured 2026-09-09.
For information about side effects caused by treatment for cancer, visit our Side Effects page.
Sources: side effects · Side Effects
Source: Gallbladder Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 10, 2025. Captured 2026-09-09.
For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.
Sources: clinical trial · standard treatment
Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.
Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.
Source: Gallbladder Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 10, 2025. Captured 2026-09-09.
Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.
Sources: side effects
Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s clinical trials search webpage. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.
Sources: clinical trials search · ClinicalTrials.gov
Source: Gallbladder Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 10, 2025. Captured 2026-09-09.
As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.
Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).
Source: Gallbladder Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 10, 2025. Captured 2026-09-09.
For information about the treatments listed below, visit the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment of localized and locally advanced gallbladder cancer may include:
Sources: localized · locally advanced
Surgery to remove the gallbladder and some of the tissue around it. Part of the liver and nearby lymph nodes may also be removed. Radiation therapy with or without chemotherapy may follow surgery.
Sources: gallbladder · liver · lymph nodes · Radiation therapy · chemotherapy
Radiation therapy with or without chemotherapy.
A clinical trial of radiation therapy with radiosensitizers.
Sources: clinical trial · radiosensitizers
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Gallbladder Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 10, 2025. Captured 2026-09-09.
For information about the treatments listed below, visit the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment of unresectable, metastatic, or recurrent gallbladder cancer is usually within a clinical trial. Treatment may include:
Sources: unresectable · metastatic · recurrent · clinical trial
Percutaneous transhepatic biliary drainage or the placement of stents to relieve symptoms caused by blocked bile ducts. This may be followed by radiation therapy as palliative treatment.
Sources: Percutaneous transhepatic biliary drainage · stents · symptoms · bile ducts · radiation therapy · palliative treatment
Surgery as palliative treatment to relieve symptoms caused by blocked bile ducts.
Chemotherapy.
Sources: Chemotherapy
A clinical trial of new ways to give palliative radiation therapy, such as giving it together with hyperthermia therapy, radiosensitizers, or chemotherapy.
Sources: hyperthermia therapy · radiosensitizers
A clinical trial of targeted therapy or immunotherapy for patients with mutations (changes) in certain genes.
Sources: targeted therapy · immunotherapy · mutations · genes
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Biliary Tract (Intrahepatic, Extrahepatic Cholangiocarcinoma, Gall Bladder) Cancer
ClinicalTrials.gov recordCancer
ClinicalTrials.gov recordBiliary Tract Neoplasms
ClinicalTrials.gov recordBiliary Tract Carcinoma
ClinicalTrials.gov recordGallbladder Cancer
Treatment of Localized and Locally Advanced Gallbladder Cancer
Treatment of Unresectable, Metastatic, or Recurrent Gallbladder Cancer
Localized (Stage I)
Unresectable, recurrent, or metastatic (Stage II, Stage III, and Stage IV)
INDICATIONS AND USAGE LOPID (gemfibrozil tablets, USP) is indicated as adjunctive therapy to diet for: 1. Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a...
DailyMed label